A Study of Bevacizumab Versus Placebo in Combination With Carboplatin/Paclitaxel in Participants With Advanced or Recurrent Non-Squamous Non-Small Cell Lung Cancer Who Have Not Received Previous Chemotherapy
Saves the questions and what to expect into your notes, next to the visit they belong to.
Keep this study
Lead
Hoffmann-La Roche
Age
18–any
Sex
ALL
Healthy volunteers
Not accepted
You may be eligible if
Locally advanced (Stage IIIb not amenable for combined modality treatment), metastatic (Stage IV) or recurrent non-squamous non-small cell lung cancer
Eastern Cooperative Oncology Group (ECOG) performance status of 0-1
Adequate hematological, renal and liver function
You may not be if
Prior chemotherapy or treatment with another systemic anti-cancer agent for the treatment of the participant's current stage of the disease (Stage IIIb, IV or recurrent disease)
Mixed non-small cell and small cell tumors or mixed adenosquamous carcinomas with a predominant squamous component
Evidence of tumor invading major blood vessels on imaging
Central nervous system (CNS) metastases, even if previously treated
History of hemoptysis in the 3 months prior to enrollment
History or evidence of inherited bleeding diathesis or coagulopathy
Uncontrolled hypertension and/or history of hypertensive crisis or hypertensive encephalopathy
Clinically significant cardiovascular or vascular disease
Malignancies other than non-small cell lung cancer within 5 years prior to randomization, except for adequately treated carcinoma in situ of the cervix, basal or squamous cell skin cancer, or localized prostate cancer or ductal carcinoma in situ treated surgically with curative intent
Clareo Health | A Study of Bevacizumab Versus Placebo in Combination With Carboplatin/Paclitaxel in Participants With Advanced or Recurrent Non-Squamous Non-Small Cell Lung Cancer Who Have Not Received Previous Chemotherapy
